A great lineup of excellent speakers at the Onc Brothers @OncBrothers event at #GI26 including our very own @TimothyJBrownMD

At Cure CRC today. ~100 of the leading colorectal cancer researchers, clinicians, advocates, and industry partners in one room, all aligned around a single goal: curing colon cancer (and me… I guess I snuck in). It’s inspiring—and also a reminder that we’re not there yet. We’re

ALASCCA showed that a century-old drug could change adjuvant outcomes in colorectal cancer. This work helps explain the biology behind that signal. New mechanistic data in NEJM identify platelet-derived thromboxane A2 as an active suppressor of antitumor immunity during

I had the chance to speak at the Northwell Health Pancreas Symposium on Emerging Therapies in PDAC. Big picture: we are not going to chemotherapy our way out of pancreatic cancer. The next gains come from biology-driven, precision strategies. A short thread 🧵👇 @OncoAlert

This is the first paper out from @TheGutOncLab @Deebacca @GIMedOnc @UGrewalMD that evaluated FOLFIRI-Ram compared to Ramucirumab-Paclitaxel in the @flatironhealth database

Great watching @UGrewalMD highlighting advances in NET care and the work being to address inequities in NET care. Also he’s now board certified!! Watch 👇🏽 @TimothyJBrownMD @TheGutOncLab https://t.co/VbssWlpDdM https://t.co/MMDjiJcl2D

Interview I did with @OncNewsCentral regarding treatment selection for 1L gastric cancer https://t.co/DqWzdbsldG @UGrewalMD @GIMedOnc @TheGutOncLab

About 2 years ago- I got a cold message from a guy who was looking for research mentorship. I reluctantly (as a fellow myself) said yes. 2 years and many manuscripts, poster presentations and concepts still in the pipeline later- I get to continue to mentor @SuriyaBaskarMD at

Match day! Looking forward to finding out who will be joining us @utswcancer @UTSWHemeOnc next year! @littlejonesmd @MonikaKumarMD @TheGutOncLab

I had the great fortune of sitting down with @PoHienEar from @UIowaCancer to discuss her ongoing work focused on GLP1 Receptor Agonists in Neuroendocrine Tumors. She was very kind to let me share the interview on my substack. Link: https://t.co/sKIgC4l14g Link to her recent

Thank you @CureNETs for the opportunity to discuss some key scientific updates from @NANETS1 2025 Annual Symposium. 🦓🎗️ Link- https://t.co/xxPyDBrhh4

Watch @GIMedOnc @TimothyJBrownMD and @UGrewalMD unpack some data from #ESMO25 for @VuMedi @VuMediHemOnc

Landmark paper from @MSKCancerCenter led by my friend @rohit_thum on landscape of DLL3 in GEP Neuroendocrine neoplasms. DLL3 is not prognostic, enriched in small cell histology and can be found in 40% of well diff G3 NENs! Functional imaging offers a promising platform for DLL3

Very excited to see this in print. Our latest commentary highlighting the "missing piece of the puzzle" in neuroendocrine neoplasm classification, published in Med @CellPressNews . NENs are classified based on morphology, site of origin, and Ki-67 proliferation indices. These

Teamed up with #BrysonKatona & #LindaLee to make sense of the ever-confusing world of #NETs in our @AGA_Gastro review—hope it helps every GI and Onc specialist who meets these sneaky tumors on a “routine” scope https://t.co/i5KN51TEyy @FoxChaseCancer @PennMedicine @BrighamWomens

Last week's episode of Oncology on the Go featured a discussion between @GIMedOnc, @UGrewalMD, and @TimothyJBrownMD about the top GI abstracts from #ESMO25! Listen here: https://t.co/4HtG3BaxLP #crcsm #NETs | @TheGutOncLab

Tune in to @colontown DocTalks to listen to Dr Hornstein discuss key colorectal cancer updates from ESMO 2025. 👇

If you’re within five years of training—or still in it—and work in neuroendocrine neoplasms (NETs/NECs), we want to hear from you!! Please fill out this survey which will help us understand early career perspectives in the field and identify areas of unmet need. Link-

4 GI Malignancy studies that we touched on with @rachnatshroff for #ESMO25: ✅ #DYNAMICIII ✅ #STELLAR303 ✅ #MATTERHORN ✅ #FORTITUDE101 #OncTwitter #MedTwitter @OncUpdates @myESMO @OncoAlert #gism

Big day for a rare disease 🎉🧬 The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer”